These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19536314)

  • 1. Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture.
    Chapurlat RD
    Ther Clin Risk Manag; 2009 Apr; 5(2):169-75. PubMed ID: 19536314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single annual injectable treatment for postmenopausal osteoporosis.
    Chapurlat RD
    Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.
    Rizzoli R
    Ther Adv Musculoskelet Dis; 2010 Feb; 2(1):3-16. PubMed ID: 22870433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Cauley JA; Cosman F; Leung PC; Lakatos P; Lippuner K; Cummings SR; Hue TF; Mukhopadhyay A; Tan M; Aftring RP; Eastell R
    J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.
    Lewiecki EM
    Core Evid; 2010 Jun; 4():13-23. PubMed ID: 20694061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
    Black DM; Reid IR; Napoli N; Ewing SK; Shiraki M; Nakamura T; Takeuchi Y; Schafer AL; Kim TY; Cauley JA
    J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
    Zhou J; Ma X; Wang T; Zhai S
    Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial.
    Cai G; Keen HI; Host LV; Aitken D; Laslett LL; Winzenberg T; Wluka AE; Black D; Jones G
    Osteoporos Int; 2020 Sep; 31(9):1741-1747. PubMed ID: 32361951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.